BAFNA PHARMACEUTICALS LTD.

Bafna Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 01, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter ending September 30, 2026. This measure is intended to prevent potential insider trading during the period leading up to and immediately following the financial results announcement.

Bafna Pharmaceuticals Ltd has announced its 31st Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 10:00 AM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has engaged CDSL for E-Voting and VC/OAVM facilities. The Annual Report for the Financial Year 2025-2026 and the AGM notice are enclosed and have been sent to members electronically. The report highlights significant growth in FY26, with operating revenue of INR 1,506 million (3.26% growth), operating profit of INR 159 million (43% growth), and net profit of INR 111 million (167% growth). Bafna Pharmaceuticals operates a manufacturing facility with Tier-1 regulatory accreditations and exports to over 20 countries.

Bafna Pharmaceuticals Ltd has released its Annual Report for FY 2025-2026, detailing significant financial growth and strategic expansion. The company reported operating revenue of INR 1,506 million, a 3.26% increase, with operating profit at INR 159 million, up 43%. Net profit saw a substantial surge of 167% to INR 111 million. The report highlights the company's expanding global footprint across 20+ countries, enhanced CRAMS capabilities, and investments in green energy and R&D. Bafna Pharmaceuticals also announced its 31st Annual General Meeting (AGM) scheduled for September 11, 2026, to be held via Video Conferencing, with CDSL providing E-Voting and VC/OAVM facilities. The company's manufacturing facility holds Tier-1 regulatory accreditations, and its export-driven model contributes significantly to revenue.

Bafna Pharmaceuticals Ltd has announced the details for its 31st Annual General Meeting (AGM), scheduled for Friday, September 11, 2026, at 10:00 AM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). In connection with the AGM, the company's Register of Members and Share Transfer Books will be closed from Saturday, September 05, 2026, to Friday, September 11, 2026, inclusive. The cut-off date for determining eligibility for remote e-voting and poll at the AGM is Friday, September 04, 2026. E-voting will commence on Tuesday, September 08, 2026, at 9:00 AM and conclude on Thursday, September 10, 2026, at 5:00 PM. CDSL has been engaged for e-voting and VC/OAVM facilities.

Bafna Pharmaceuticals Ltd has announced that its 31st Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 10:00 AM IST. The meeting will be conducted entirely through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has also set the book closure period from September 5, 2026, to September 11, 2026, inclusive. E-voting will be available from September 8, 2026 (9:00 AM) to September 10, 2026 (5:00 PM), with the cut-off date for eligibility being September 4, 2026. Central Depository Services (India) Limited (CDSL) will provide the e-voting and VC/OAVM facilities.

Bafna Pharmaceuticals Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results on August 11, 2026. The company also announced its 31st Annual General Meeting (AGM) will be held on September 11, 2026, through Video Conferencing. The book closure for the AGM will be from September 5 to September 11, 2026, with a cut-off date of September 4, 2026, for determining voting eligibility. The Board meeting to approve these results commenced at 2:30 PM and concluded at 4:00 PM IST.

Bafna Pharmaceuticals Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors also approved the limited review report. The company has scheduled its 31st Annual General Meeting (AGM) for September 11, 2026, to be held via Video Conferencing. Book closure for the AGM will be from September 5 to September 11, 2026, with a cut-off date of September 4, 2026, for determining voting eligibility.

Bafna Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 11, 2026. The primary agenda item for this meeting is to consider and approve the Un-Audited Financial Results for the first quarter ended June 30, 2026. In line with SEBI regulations and the company's insider trading code, the trading window for designated persons and their immediate relatives will remain closed from July 1, 2026, to August 13, 2026, inclusive, to prevent potential misuse of information related to the financial results.

Bafna Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. This measure is intended to prevent potential insider trading activities during the period leading up to and immediately following the financial results announcement.

Bafna Pharmaceuticals Ltd announced the retirement of Mr. Navin Kumar as an Independent Director, effective June 22, 2026, upon completion of his first term. Consequently, he will also step down as Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has reconstituted these committees effective June 23, 2026, with new chairpersons and members appointed. Bafna Pharmaceuticals confirmed that the board and committee compositions remain compliant with applicable regulations.